Read more
6:19 PM ยท 2 January 2024

Moderna gains over 14% after bullish recommendations ๐Ÿ“Œ

Moderna is gaining 14.30% marking the highest intraday gain since late 2022 following an upgrade by Oppenheimer from Perform to Outperform. The investment bank highlighted the company's promising commercial prospects and advancements in its pipeline. The upgrade aligns with CEO Stéphane Bancel's 2023 shareholder letter, which highlighted Moderna's increased US market share for its COVID-19 vaccine. Analyst from Oppenheimer predicts Moderna will become one of the leading players in its sector by 2026, with sales growth accelerating in 2025 driven by multiple product launches, including vaccines against respiratory syncytial virus and influenza.

In 2023 Moderna was among the worst performing companies in the S&P 500 due to declining Covid-19 vaccine sales. The average analyst price target for Moderna is $126, suggesting potential upward momentum compared to the current price of $113 per share.

Source: xStation 5

8 May 2026, 5:43 PM

Microsoft: Hedge Fund Sharply Cuts Position and Warns About AI Risks

8 May 2026, 4:34 PM

Cloudflare: strong results, weak outlook, and a painful market reaction

8 May 2026, 3:33 PM

US Open: Earnings season and strong NFP report drive Wall Street higher!

8 May 2026, 12:59 PM

CoreWeave results: Expansion without profit and without direction

The financial instruments we offer, especially CFDs, can be highly risky. Fractional Shares (FS) is an acquired from XTB fiduciary right to fractional parts of stocks and ETFs. FS are not a separate financial instrument. The limited corporate rights are associated with FS.
This page was not created for investors residing in Brazil. This brokerage is not authorized by the Comissรฃo de Valores Mobiliรกrios (CVM) or the Brazilian Central Bank (BCB). The content of this page should not be characterized as an investment offer in Brazil or for investors residing in that country.
Losses can exceed deposits